Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent synovitis, cartilage damage and bone degradation. Interleukin-17A (IL-17A) is a cytokine secreted primarily by T helper 17 (Th17) cells and also by CD8+ T (Tc17) cells, γδ T cells, invariant natural killer T cells, mucosal-associated invariant T cells, and group 3 innate lymphoid cells. IL-17A has been implicated in the etiology of RA, both by the association of immunological activation with synovial inflammation and structural joint damage. IL-17A acts on synovial fibroblasts and a range of immune and stromal cells together with inflammatory cytokines, especially tumor necrosis factor-α (TNF-α), to induce the production of cytokines and chemokines, matrix breakdown and Receptor activator of nuclear factor-κB ligand (RANKL)-dependent osteoclastogenesis in RA. IL-17A has been shown to be involved in synovitis and joint destruction in experimental arthritic models. Despite a strong molecular and preclinical rationale, clinical studies of IL-17-targeting therapies in RA have demonstrated uneven and generally limited efficacy. This discrepancy may reflect the molecular and cellular heterogeneity of RA, redundancy of cytokines, differences in disease progression and tissue environment, and the lack of validated biomarkers for IL17A-dependent disease. This review critically examines the signaling of IL-17A, its pathogenic and structural roles in RA, evidence from experimental arthritis models, and the clinical outcomes and limitations of IL-17-targeted therapies. Emerging approaches, including biomarker-guided patient stratification, single-cell and spatial profiling, multi-omics, broader cytokine targeting, and modulation of immune system and metabolic processes and gutjoint pathways, are also discussed. We also discuss current studies which suggest the future clinical relevance of IL-17A in patients with RA IL-17A is a main and therapeutically targetable inflammatory mechanism.

Authors

Institutions

Publication Details

Journal
Molecules
Published
2026-11-19
DOI
https://doi.org/10.3390/molecules31224198
Primary Topic
Rheumatoid Arthritis Research and Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions

Waqar Ahmad, Katarína Bauerová, Mohammad Umar, Muhammad Adil Khan
Molecules
Rheumatoid Arthritis Research and Therapies
article

Interleukin-17A as a Key Mediator and Therapeutic Target in Rheumatoid Arthritis: Current Evidence and Future Directions

Waqar Ahmad, Katarína Bauerová, Mohammad Umar, Muhammad Adil Khan
article en

Abstract

Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent synovitis, cartilage damage and bone degradation. Interleukin-17A (IL-17A) is a cytokine secreted primarily by T helper 17 (Th17) cells and also by CD8+ T (Tc17) cells, γδ T cells, invariant natural killer T cells, mucosal-associated invariant T cells, and group 3 innate lymphoid cells. IL-17A has been implicated in the etiology of RA, both by the association of immunological activation with synovial inflammation and structural joint damage. IL-17A acts on synovial fibroblasts and a range of immune and stromal cells together with inflammatory cytokines, especially tumor necrosis factor-α (TNF-α), to induce the production of cytokines and chemokines, matrix breakdown and Receptor activator of nuclear factor-κB ligand (RANKL)-dependent osteoclastogenesis in RA. IL-17A has been shown to be involved in synovitis and joint destruction in experimental arthritic models. Despite a strong molecular and preclinical rationale, clinical studies of IL-17-targeting therapies in RA have demonstrated uneven and generally limited efficacy. This discrepancy may reflect the molecular and cellular heterogeneity of RA, redundancy of cytokines, differences in disease progression and tissue environment, and the lack of validated biomarkers for IL17A-dependent disease. This review critically examines the signaling of IL-17A, its pathogenic and structural roles in RA, evidence from experimental arthritis models, and the clinical outcomes and limitations of IL-17-targeted therapies. Emerging approaches, including biomarker-guided patient stratification, single-cell and spatial profiling, multi-omics, broader cytokine targeting, and modulation of immune system and metabolic processes and gutjoint pathways, are also discussed. We also discuss current studies which suggest the future clinical relevance of IL-17A in patients with RA IL-17A is a main and therapeutically targetable inflammatory mechanism.

MoleculesVol. 31(22)
Slovak Academy of Sciences (SK), Centre of Experimental Medicine of the Slovak Academy of Sciences (SK), Institute of Experimental Pharmacology and Toxicology of the Slovak Academy of Sciences (SK), Comenius University Bratislava (SK)
Rheumatoid Arthritis Research and Therapies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon